[Comment] PARP inhibitors: pitfalls and promises

20:41 EDT 27 Jun 2013 | The Lancet

Enthusiasm swelled for inhibition of poly(ADP-ribose) polymerase (PARP) as a treatment strategy in oncology when the oral inhibitor of PARP-1 and PARP-2 olaparib produced durable responses in patients with ovarian and breast cancer and BRCA mutations...

Original Article: [Comment] PARP inhibitors: pitfalls and promises

NEXT ARTICLE

More From BioPortfolio on "[Comment] PARP inhibitors: pitfalls and promises"

Search BioPortfolio:
Advertisement

Relevant Topics

Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue, including organs.  Cancer sometimes begins in one part of the body before spre...

Breast Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Top five promising drugs Phase III (November 2013)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS ENTERING PHASE III TRIALS DRUG DISEASE COMPANY BMN-673 BRCA-mutation-positive breast cancer Biomarin Pharmaceuticals eravacycline Complicated...

Advertisement

Searches Linking to this Story